Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
Abstract
The anti-programmed cell death-1 protein monoclonal antibody, pembrolizumab is an immune checkpoint inhibitor. While it improves the prognoses of patients with advanced non-small-cell lung cancer, it has been reported to induce various kinds of immune-related adverse events, including hepatotoxicity. Despite the frequency of hepatotoxicity, there is only limited information available regarding the pathophysiology and treatment. We herein report...
Paper Details
Title
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
Published Date
Nov 15, 2019
Journal
Volume
58
Issue
22
Pages
3283 - 3287
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History